Daclatasvir
- Generic Name
- Daclatasvir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C40H50N8O6
- CAS Number
- 1009119-64-5
- Unique Ingredient Identifier
- LI2427F9CI
- Background
Daclatasvir is a direct-acting antiviral agent against Hepatitis C Virus (HCV) used for the treatment of chronic HCV genotype 1 and 3 infection. It is marketed under the name DAKLINZA and is contained in daily oral tablets as the hydrochloride salt form . Hepatitis C is an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a si...
- Indication
Indicated for use with sofosbuvir, with or without ribavirin, for the treatment of chronic HCV genotype 1a/b or 3 infection. The dosing regimen of 60mg daclatasvir 60 mg with 400mg sofosbuvir once a day is recommended for both genontypes.
...
- Associated Conditions
- Chronic Hepatitis C - Genotype 3, Chronic Hepatitis C Genotype 1, Chronic Hepatitis C Virus (HCV) Infection, Chronic hepatitis C genotype 2
- Associated Therapies
- -
Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus
- Conditions
- Interventions
- First Posted Date
- 2011-11-15
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 549
- Registration Number
- NCT01471574
- Locations
- 🇺🇸
Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸Icahn School Of Medicine At Mount Sinai, New York, New York, United States
🇺🇸San Francisco Gen Hosp, San Francisco, California, United States
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
- Conditions
- Interventions
- First Posted Date
- 2011-10-19
- Last Posted Date
- 2017-04-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 320
- Registration Number
- NCT01455090
- Locations
- 🇵🇷
Fundacion De Investigacion De Diego, San Juan, Puerto Rico
🇺🇸James J Peters Vamc, The Bronx, New York, United States
🇺🇸Inova Fairfax Hospital, Falls Church, Virginia, United States
Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials
- Conditions
- Interventions
- First Posted Date
- 2011-09-02
- Last Posted Date
- 2016-05-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 276
- Registration Number
- NCT01428063
- Locations
- 🇺🇸
Scpmg/ Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸Mercy Medical Center, Baltimore, Maryland, United States
🇺🇸University Of Pennsylvania, Philadelphia, Pennsylvania, United States
Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin
- Conditions
- Interventions
- First Posted Date
- 2011-08-30
- Last Posted Date
- 2015-11-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 210
- Registration Number
- NCT01425970
- Locations
- 🇺🇸
Alamo Medical Research, San Antonio, Texas, United States
🇺🇸Options Health Research, Llc, Tulsa, Oklahoma, United States
🇺🇸Quest Clinical Research, San Francisco, California, United States
BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2011-07-08
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 448
- Registration Number
- NCT01389323
- Locations
- 🇺🇸
Greater Los Angeles Healthcare System, Los Angeles, California, United States
🇺🇸Triple O Research Institute, P.A., West Palm Beach, Florida, United States
🇺🇸University Of Miami, Miami, Florida, United States
Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care
- Conditions
- Interventions
- First Posted Date
- 2011-05-25
- Last Posted Date
- 2015-10-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 350
- Registration Number
- NCT01359644
- Locations
- 🇺🇸
Mercy Medical Center, Baltimore, Maryland, United States
🇺🇸Research And Education, Inc., San Diego, California, United States
🇺🇸University Of Florida Hepatology, Gainesville, Florida, United States
Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection
- Conditions
- Interventions
- First Posted Date
- 2010-12-09
- Last Posted Date
- 2015-12-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 196
- Registration Number
- NCT01257204
- Locations
- 🇺🇸
California Liver Institute, Los Angeles, California, United States
🇮🇹Local Institution, Viale Del Policlinico, 155, Italy
🇺🇸Options Health Research, Llc, Tulsa, Oklahoma, United States
Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment
- Conditions
- Interventions
- First Posted Date
- 2010-07-28
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 512
- Registration Number
- NCT01170962
- Locations
- 🇺🇸
Scripps Clinic, La Jolla, California, United States
🇺🇸Alabama Liver & Digestive Specialists (Alds), Montgomery, Alabama, United States
🇺🇸Liver Associates Of Texas, Houston, Texas, United States
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
- Conditions
- Interventions
- First Posted Date
- 2010-05-18
- Last Posted Date
- 2015-10-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 558
- Registration Number
- NCT01125189
- Locations
- 🇺🇸
University Of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Johns Hopkins University, Lutherville, Maryland, United States
🇺🇸Cli, Los Angeles, California, United States
An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject
- First Posted Date
- 2010-01-18
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 43
- Registration Number
- NCT01051414
- Locations
- 🇯🇵
Local Institution, Minato-Ku, Tokyo, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.